West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
wst · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for West Pharmaceutical Services, Inc. (WST) measures how much investors pay for each dollar of the company's trailing earnings. WST's current PE ratio of 41.72x is calculated by dividing its stock price of $314.50 by its TTM earnings per share of $7.54. −3.2% discount vs 5Y avg 43.1x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%32.7x
MedianQ3 · 75%60.5x
Max
At 41.72x, WST's current P/E is within its average historical range over the past 20 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Instruments & Supplies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
West Pharmaceutical Services, Inc.You WST | $22.2B | 41.72x | +70.3% | $7.54 |
 The Cooper Companies, Inc. COO | $13.1B | 37.30x | +52.2% | $1.87 |
 Quest Diagnostics Incorporated DGX | $22.2B | 19.42x | -20.8% | $8.94 |
 Hologic, Inc. HOLX | $17.0B | 26.99x | +10.2% | $2.49 |
 Illumina, Inc. ILMN | $24.6B | 24.52x | +0.1% | $5.48 |
 Incyte Corporation INCY | $20.5B | 14.98x | -38.8% | $6.59 |
 Labcorp Holdings Inc. LH | $21.7B | 23.81x | -2.8% | $10.53 |
Industry Average 6 peers with valid PE | — | 24.50x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 40.29x | $6.83 | -17.0% | |
2024-12-31 FY2024 | 48.53x | $6.75 | +10.1% | |
2023-12-31 FY2023 | 44.09x | $7.99 | +47.5% | |
2022-12-31 FY2022 | 29.89x | $7.88 | -43.3% | |
2021-12-31 FY2021 | 52.73x | $8.90 | -12.8% | |
2020-12-31 FY2020 | 60.48x | $4.68 | +31.4% | |
2019-12-31 FY2019 | 46.03x | $3.27 | +31.4% | |
2018-12-31 FY2018 | 35.01x | $2.80 | -27.6% | |
2017-12-31 FY2017 | 48.39x | $2.04 | +11.7% | |
2016-12-31 FY2016 | 43.30x | $1.96 | -4.5% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for West Pharmaceutical Services, Inc. (WST) measures how much investors pay for each dollar of the company's trailing earnings. WST's current PE ratio of 41.72x is calculated by dividing its stock price of $314.50 by its TTM earnings per share of $7.54.
Frequently asked questions
WST pe ratio · 6 questionsWST's current PE ratio is 41.72x as of 2026-06-08, based on a stock price of $314.50 and TTM EPS of $7.54. Data sourced from Financial Modeling Prep via WST's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · West Pharmaceutical Services, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08